Work

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas

Year: 2016

Type: article

Study design: Clinical Trial

Source: Cancer Immunology Immunotherapy

DOI: 10.1007/s00262-016-1893-7

Authors: Megan C. Duggan, Caroline Jochems, Renee N. Donahue, Jacob Richards, Volodymyr Karpa, Elizabeth Foust, Bonnie Paul, Taylor Brooks, Susheela Tridandapani, Thomas Olencki, Xueliang Pan, Gregory B. Lesinski, Jeffrey Schlom, William E. Carson III

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, National Cancer Institute, United States Food and Drug Administration, Center for Devices and Radiological Health

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: Innate Immunity: Elucidation and Modulation for Cancer Therapy, Integrative training in biomedical systems, Cancer Center Support Grant

OpenAlex ID: W2517830319

FWCI: 2.267

Cites: 47

Cited by: 35

Related to: 10